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PurposeRapid advances in the understanding of cancer biology have transformed
drug development thus leading to the approval of targeted therapies and to the
development of molecular tests to select patients that will respond to treatments.
KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR
antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS
wild type tumors. In order to ensure wide access to tumor molecular profiling, the
French National Cancer Institute (INCa) has set up a national network of 28 regional
molecular genetics centers. Concurrently, a nationwide external quality assessment
for KRAS testing (MOKAECM) was granted to analyze reproducibility and costs.
Methods 96 cell-line DNAs and 24 DNA samples from paraffin embedded tumor
tissues were sent to 40 French laboratories. A total of 5448 KRAS results were
collected and analyzed and a micro-costing study was performed on sites for 5
common methods by an independent team of health economists. Results This work
provided a baseline picture of the accuracy and reliability of KRAS analysis in routine
testing conditions at a nationwide level. Inter-laboratory Kappa values were >0.8 for
KRAS results despite differences detection methods and the use of in-house
technologies. Specificity was excellent with only one false positive in 1128 FFPE data,
and sensitivity was higher for targeted techniques as compared to Sanger sequencing
based methods that were dependent upon local expertise. Estimated reagent costs
per patient ranged from €5.5 to €19.0. Conclusion The INCa has set-up a network of
public laboratories dedicated to molecular oncology tests. Our results showed almost
perfect agreements in KRAS testing at a nationwide level despite different testing
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